Romdhane, Khaled <br/><br/>
Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.  [electronic resource] 

 -  The British journal of ophthalmology  07 2020 
 - 910-916 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1468-2079 
<br/><br/><label>Standard No.: </label>10.1136/bjophthalmol-2019-314625  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Angiogenesis Inhibitors--therapeutic use<br/>Central Serous Chorioretinopathy--complications<br/>Choroidal Neovascularization--diagnostic imaging<br/>Chronic Disease<br/>Coloring Agents--administration & dosage<br/>Female<br/>Fluorescein Angiography<br/>Humans<br/>Indocyanine Green--administration & dosage<br/>Intravitreal Injections<br/>Male<br/>Middle Aged<br/>Multimodal Imaging<br/>Ranibizumab--therapeutic use<br/>Receptors, Vascular Endothelial Growth Factor--therapeutic use<br/>Recombinant Fusion Proteins--therapeutic use<br/>Retrospective Studies<br/>Subretinal Fluid<br/>Tomography, Optical Coherence<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--physiology